Vaping: Respiratory Care and Clinical Considerations

Vaping has become an important respiratory health concern because electronic cigarettes and similar devices can expose the lungs to nicotine, chemicals, ultrafine particles, flavoring agents, and other potentially harmful substances.

Respiratory therapists may encounter patients who vape during routine assessment, pulmonary testing, emergency care, or treatment of acute lung injury.

Understanding how vaping affects the respiratory system can help respiratory therapists recognize associated symptoms, identify potential complications, support diagnostic evaluation, provide appropriate respiratory care, and educate patients about the pulmonary risks associated with inhaling aerosolized substances.

What Is Vaping?

Vaping refers to the inhalation of an aerosol produced by an electronic cigarette, vape pen, pod system, electronic nicotine delivery system, or similar device. These devices typically use a battery-powered heating element to heat a liquid or other substance, producing an aerosol that is inhaled into the lungs.

Although vaping is sometimes described as producing water vapor, the inhaled material is not simply water. Vape aerosols may contain nicotine, propylene glycol, vegetable glycerin, flavoring chemicals, volatile organic compounds, ultrafine particles, metals, and other substances generated or released during heating.

Some devices are used to inhale nicotine-containing liquids, while others may contain tetrahydrocannabinol, commonly known as THC, cannabidiol, or other substances. The exact contents of a vaping product can vary substantially depending on the manufacturer, device, liquid formulation, additives, temperature settings, and whether the product has been modified.

For respiratory therapists, this variability is clinically important because two patients who report vaping may have been exposed to very different substances and concentrations.

How Vaping Devices Work

Most vaping devices contain several basic components:

• A battery or power source
• A heating element or coil
• A cartridge, pod, or reservoir
• A liquid or inhaled substance
• A mouthpiece

When the device is activated, electrical energy heats the liquid or other material. The resulting aerosol is inhaled through the mouthpiece and transported through the upper and lower respiratory tract.

Some vaping devices automatically activate when the user inhales, while others require the user to press a button. More powerful devices may allow users to modify voltage, wattage, airflow, or coil temperature.

Higher temperatures may increase aerosol production but can also alter the chemical composition of the inhaled aerosol. Heating certain ingredients can create additional compounds that were not originally present in the liquid.

Common Components of Vape Aerosols

The respiratory effects of vaping depend partly on the substances being inhaled. Vape aerosols can contain a mixture of chemicals and particles that may irritate or injure respiratory tissues.

Nicotine

Many vaping products contain nicotine. Nicotine is highly addictive and can produce cardiovascular and neurologic effects, including increased heart rate, increased blood pressure, and stimulation of the sympathetic nervous system.

Some modern vaping products contain nicotine salts, which allow relatively high concentrations of nicotine to be inhaled with less throat irritation than some traditional formulations. This can make substantial nicotine exposure possible even when the user does not perceive the aerosol as particularly harsh.

Propylene Glycol and Vegetable Glycerin

Propylene glycol and vegetable glycerin are commonly used as carrier liquids in electronic cigarette products. When heated, they produce the visible aerosol inhaled by the user.

These substances may also break down during heating and produce irritating compounds. Repeated inhalation can contribute to airway irritation and inflammation, particularly in susceptible individuals.

Flavoring Chemicals

Thousands of flavor combinations have been used in vaping products. A chemical that is considered acceptable for ingestion is not necessarily safe when heated and inhaled directly into the lungs.

Flavoring agents may interact with airway epithelial cells and other components of the respiratory system. Some can contribute to inflammation, oxidative stress, or cellular injury.

Metals

Metals may enter vape aerosols from heating coils and other components of the device. Depending on the product, aerosols may contain substances such as nickel, chromium, lead, or other metals.

Repeated inhalation of metal-containing particles is a respiratory concern because these materials can reach the lower airways and alveolar regions.

THC and Other Substances

Some vaping devices are used to inhale THC-containing oils or concentrates. This is especially relevant when evaluating patients with suspected vaping-related lung injury.

Patients may not initially volunteer information about THC use. A nonjudgmental respiratory and substance-use history can help obtain more accurate information.

Respiratory Effects of Vaping

Vaping can affect the respiratory system through several mechanisms, including airway irritation, inflammation, oxidative stress, epithelial injury, impaired immune defenses, and changes in airway reactivity.

The degree of injury can vary widely. Some individuals experience mild symptoms, while others develop severe respiratory impairment.

Airway Irritation

One of the most common effects associated with vaping is irritation of the respiratory tract. Patients may report coughing, throat irritation, chest discomfort, or increased mucus production.

Repeated exposure to heated aerosols can irritate the airway epithelium and promote inflammatory responses. These effects may be particularly noticeable in patients with preexisting asthma or other airway disorders.

Airway Inflammation

Vaping aerosols may trigger inflammatory changes within the bronchial tree and distal lung tissue. Inflammation can contribute to airway narrowing, increased mucus production, and respiratory symptoms.

Inflammatory effects may also increase airway sensitivity, potentially worsening symptoms in individuals with reactive airway disease.

Oxidative Stress

Certain chemicals in vaping aerosols can promote oxidative stress. This occurs when reactive molecules exceed the body’s ability to neutralize them effectively.

Oxidative stress can contribute to cellular injury, inflammatory signaling, and impaired function of respiratory epithelial cells.

Impaired Mucociliary Clearance

The mucociliary system helps remove inhaled particles, microorganisms, and secretions from the airways. Exposure to vaping aerosols may interfere with normal ciliary function and mucus transport. Reduced mucociliary clearance can make it more difficult for the lungs to eliminate contaminants and secretions.

Effects on Pulmonary Immune Defense

The lungs depend on several immune mechanisms to protect against infection and inhaled contaminants. Vaping may alter the function of macrophages, epithelial cells, and other immune components.

These effects may potentially impair normal pulmonary defense mechanisms, although the clinical significance varies depending on exposure, patient characteristics, and other risk factors.

Vaping and Asthma

Vaping is particularly relevant in patients with asthma because inhaled aerosols can irritate hyperresponsive airways. A patient with asthma who vapes may experience increased coughing, wheezing, chest tightness, or shortness of breath. Vaping exposure may trigger bronchospasm or contribute to worsening asthma symptoms in susceptible individuals.

Respiratory therapists should include vaping history when assessing patients with poorly controlled asthma or unexplained increases in respiratory symptoms.

Important assessment questions may include the type of device used, substances inhaled, frequency of use, recent changes in products, and whether symptoms worsen after vaping.

During an acute asthma exacerbation, treatment should focus on standard clinical management, including assessment of severity, bronchodilator therapy, oxygen when indicated, corticosteroid treatment as ordered, and escalation of respiratory support when necessary.

Vaping and Chronic Respiratory Disease

The long-term respiratory effects of vaping continue to be studied, particularly because widespread use of modern electronic cigarette products is relatively recent compared with conventional cigarette smoking.

Repeated airway exposure to irritants and inflammatory substances raises concern for chronic respiratory symptoms and impaired pulmonary function over time.

Patients with COPD, chronic bronchitis, bronchiectasis, cystic fibrosis, or other pulmonary disorders may be especially vulnerable to the respiratory effects of vaping because they already have reduced pulmonary reserve or impaired airway clearance. Respiratory therapists should not assume that electronic cigarettes are harmless simply because they do not produce tobacco smoke.

E-Cigarette or Vaping Product Use-Associated Lung Injury

One of the most serious pulmonary complications associated with vaping is e-cigarette or vaping product use-associated lung injury, commonly abbreviated EVALI.

EVALI gained widespread attention after a large outbreak of severe lung injury occurred in the United States in 2019. Many affected patients reported using THC-containing vaping products, and vitamin E acetate was strongly associated with the outbreak.

EVALI is a clinical syndrome rather than a single pathologic diagnosis. Patients can present with varying patterns of lung injury, and diagnosis requires consideration of vaping exposure along with clinical findings and exclusion of other potential causes.

Signs and Symptoms of EVALI

Patients with EVALI commonly present with respiratory symptoms, but constitutional and gastrointestinal symptoms may also occur.

Respiratory Symptoms

Common respiratory complaints include:

• Shortness of breath
• Cough
• Chest pain
• Tachypnea
• Hypoxemia

Note: Some patients initially have relatively mild symptoms that progress over several days.

Constitutional Symptoms

Systemic symptoms may include fever, chills, fatigue, malaise, or weight loss. These findings can make the illness resemble pneumonia, influenza, or another infectious process.

Gastrointestinal Symptoms

Gastrointestinal symptoms are common in EVALI and may include nausea, vomiting, abdominal discomfort, or diarrhea. This is an important clinical point because a patient presenting with respiratory symptoms and recent vaping history may also report significant gastrointestinal complaints.

Clinical Assessment of a Patient Who Vapes

Respiratory therapists frequently participate in the initial assessment of patients with respiratory symptoms. A detailed vaping history can provide valuable diagnostic information.

Questions should be asked in a neutral, nonjudgmental manner. Patients may be reluctant to disclose nicotine, THC, or other substance use if they feel they are being judged.

Vaping History

A useful history may include:

• Whether the patient currently vapes
• How frequently the patient vapes
• Duration of vaping history
• Device type
• Nicotine use
• THC or cannabis product use
• Other substances inhaled
• Source of vaping products
• Recent changes in products
• Use of modified or homemade cartridges
• Time between exposure and onset of symptoms

Note: The clinician should also determine whether the patient smokes conventional cigarettes, uses smokeless tobacco, or has other inhalational exposures.

Respiratory Assessment

The respiratory assessment should include evaluation of breathing pattern, work of breathing, respiratory rate, oxygen saturation, breath sounds, cough, sputum production, and overall appearance.

Signs of respiratory compromise may include tachypnea, accessory muscle use, cyanosis, inability to speak in full sentences, altered mental status, or rapidly declining oxygen saturation. Patients with severe disease may require immediate stabilization before a detailed history can be obtained.

Pulse Oximetry

Pulse oximetry is commonly used to evaluate oxygenation in patients with suspected vaping-related respiratory illness. A reduced SpO₂ may indicate significant impairment in gas exchange, especially when accompanied by dyspnea, tachypnea, or abnormal imaging.

Continuous pulse oximetry may be appropriate in patients with moderate or severe respiratory symptoms.

Respiratory therapists should interpret oxygen saturation in the context of the patient’s overall clinical condition, oxygen delivery device, perfusion, and other factors that can affect measurement accuracy.

Arterial Blood Gas Analysis

An arterial blood gas may be obtained when significant respiratory impairment is suspected.

ABG analysis can help evaluate:

• Oxygenation
• Ventilation
• Acid-base status
• Severity of respiratory failure
• Response to respiratory support

Note: A patient with severe vaping-related lung injury may develop substantial hypoxemia. PaCO₂ may initially be normal or reduced because of tachypnea and hyperventilation. A rising PaCO₂ in a patient with worsening respiratory distress may indicate fatigue, reduced alveolar ventilation, or progression toward ventilatory failure.

Imaging

Chest imaging is often important when evaluating suspected vaping-related lung injury. Chest radiographs may demonstrate bilateral pulmonary infiltrates or other abnormalities. However, radiographic findings can vary, and a normal or mildly abnormal chest x-ray does not always exclude significant disease.

Computed tomography may reveal more extensive pulmonary abnormalities, including ground-glass opacities and bilateral infiltrative patterns. Imaging findings are not specific for EVALI and can overlap with pneumonia, acute respiratory distress syndrome, pulmonary edema, and other conditions.

Pulmonary Function Testing

Pulmonary function testing is generally not the primary diagnostic tool during acute severe vaping-related lung injury. However, spirometry or other pulmonary function studies may be useful in stable patients with chronic respiratory symptoms associated with vaping.

Testing may help identify airflow obstruction, restrictive abnormalities, air trapping, or reduced diffusion capacity. Results should be interpreted alongside clinical history and other diagnostic findings.

Differential Diagnosis

Respiratory symptoms in a patient who vapes should not automatically be attributed to vaping.

Several conditions can produce similar findings, including:

• Bacterial pneumonia
• Viral pneumonia
• Influenza
• COVID-19
• Asthma exacerbation
• COPD exacerbation
• Pulmonary embolism
• Pneumothorax
• Pulmonary edema
• Acute respiratory distress syndrome
• Toxic inhalation injury

Note: EVALI is generally considered a diagnosis of exclusion because there is no single diagnostic test that definitively confirms the condition. A patient may also have more than one problem at the same time. For example, someone who vapes may still develop a bacterial or viral respiratory infection.

Respiratory Care for Vaping-Related Lung Injury

Respiratory management depends on the severity of the patient’s condition. Some patients require only observation and supportive care, while others may require supplemental oxygen, high-flow oxygen therapy, noninvasive respiratory support, or invasive mechanical ventilation.

Supplemental Oxygen

Oxygen therapy should be administered when clinically indicated to correct hypoxemia. The respiratory therapist should select an appropriate device based on oxygen requirements, patient tolerance, work of breathing, and overall condition.

Possible oxygen delivery methods include nasal cannula, simple mask, air-entrainment mask, reservoir mask, or high-flow nasal cannula. Patients should be reassessed frequently because oxygen requirements may change rapidly.

High-Flow Nasal Cannula

High-flow nasal cannula may be useful in selected patients with acute hypoxemic respiratory failure.

HFNC can provide high gas flow, adjustable oxygen concentration, heated humidification, and a degree of positive airway pressure. It may reduce work of breathing and improve oxygenation in appropriate patients.

The patient’s respiratory rate, oxygen saturation, mental status, breathing pattern, and overall clinical response should be closely monitored. Failure to improve should prompt consideration of escalation in respiratory support.

Noninvasive Ventilation

Noninvasive ventilation may be considered in selected patients, depending on the nature of respiratory failure and the patient’s clinical status.

However, NIV should not delay intubation when a patient has worsening hypoxemia, severe respiratory distress, deteriorating mental status, inability to protect the airway, or other signs of impending respiratory failure. Careful monitoring is essential because patients with acute lung injury can deteriorate quickly.

Mechanical Ventilation

Patients with severe vaping-related lung injury may develop acute hypoxemic respiratory failure requiring endotracheal intubation and mechanical ventilation. Ventilator management should be based on the patient’s underlying physiology and severity of lung injury.

When the clinical picture resembles ARDS, lung-protective ventilation strategies may be appropriate.

Typical considerations include:

• Lower tidal volume ventilation based on predicted body weight
• Limiting excessive plateau pressure
• Appropriate PEEP
• Careful oxygen titration
• Monitoring respiratory system compliance
• Avoiding excessive ventilator-induced stress

Note: The respiratory therapist should closely monitor airway pressures, tidal volumes, minute ventilation, oxygenation, blood gases, and patient-ventilator synchrony.

Vaping and Acute Respiratory Distress Syndrome

Severe vaping-related lung injury can produce a clinical picture similar to acute respiratory distress syndrome. ARDS is characterized by diffuse inflammatory lung injury, impaired gas exchange, reduced pulmonary compliance, and severe hypoxemia.

Patients may require increasing FiO₂ and PEEP to maintain acceptable oxygenation. In severe cases, prone positioning, neuromuscular blockade, or other advanced strategies may be considered according to established critical care protocols.

For respiratory therapists, careful monitoring of plateau pressure, driving pressure, oxygenation, ventilator synchrony, and response to PEEP adjustments is important.

Aerosolized Medications

Some patients who vape may present with bronchospasm or an exacerbation of underlying asthma or COPD. Bronchodilator therapy may be prescribed when reversible airflow obstruction is present.

Common treatments can include short-acting beta agonists such as albuterol and, in some cases, anticholinergic bronchodilators. Nebulized therapy should be based on the patient’s clinical findings rather than vaping history alone.

A patient with vaping-related lung injury does not automatically require bronchodilator therapy unless bronchospasm or airflow obstruction is present.

Corticosteroids

Systemic corticosteroids have been used in some patients with EVALI, particularly when significant inflammatory lung injury is suspected. Clinical improvement has been reported in some cases, but corticosteroid use should be guided by the treating physician and the patient’s overall clinical situation.

Infection should remain part of the differential diagnosis because corticosteroids can affect immune function and potentially complicate infectious disease. Respiratory therapists should monitor the patient’s response to therapy while continuing respiratory support as needed.

Airway Management

Severely ill patients may require advanced airway management. Indications for intubation can include worsening hypoxemia despite oxygen therapy, severe respiratory distress, declining mental status, inability to protect the airway, exhaustion, or progressive ventilatory failure.

Before intubation, the respiratory therapist may assist with equipment preparation, oxygenation, suction setup, ventilator preparation, and confirmation of airway placement. After intubation, continuous assessment of ventilation and oxygenation is required.

Monitoring the Hospitalized Patient

Patients admitted with significant vaping-related respiratory illness should be monitored for deterioration.

Important variables may include:

• Respiratory rate
• SpO₂
• Oxygen requirement
• Heart rate
• Blood pressure
• Mental status
• Work of breathing
• Breath sounds
• ABG results when indicated
• Chest imaging
• Ventilator parameters if mechanically ventilated

Note: A rising oxygen requirement or increasing work of breathing may indicate progression of lung injury. Respiratory therapists are often in a position to recognize these changes early because they repeatedly assess the patient while delivering respiratory treatments and oxygen therapy.

Vaping and Pneumothorax

Although uncommon, vaping has been associated with reports of spontaneous pneumothorax and other barotrauma-like complications. Patients who present with sudden chest pain and shortness of breath should be evaluated for pneumothorax, particularly when breath sounds are asymmetric or respiratory distress develops abruptly.

A chest radiograph or other imaging study is typically required to confirm the diagnosis. Respiratory therapists should recognize that acute dyspnea in someone who vapes is not always caused by airway irritation or EVALI.

Vaping and Infection Risk

Vaping may affect airway defenses and inflammatory responses, but respiratory infection must still be evaluated using standard clinical principles. Symptoms such as fever, cough, sputum production, dyspnea, and abnormal imaging can occur with both infection and vaping-related lung injury.

Laboratory testing, imaging, cultures, viral testing, and other diagnostic studies may be needed to distinguish between potential causes. Empiric antimicrobial therapy may be initiated when bacterial infection cannot initially be excluded.

Nicotine Dependence

Nicotine dependence is an important component of respiratory care because many patients who vape regularly may experience withdrawal when they stop using nicotine. Symptoms of nicotine withdrawal can include irritability, anxiety, restlessness, difficulty concentrating, and strong cravings.

Hospitalization may provide an opportunity for smoking and vaping cessation counseling. Respiratory therapists can reinforce cessation recommendations and direct patients toward appropriate resources without using a confrontational approach.

Patient Education

Patient education should focus on the respiratory risks associated with inhaling aerosolized chemicals and particles. Patients may incorrectly believe that vaping is harmless because it does not produce cigarette smoke. Education can clarify that the absence of tobacco combustion does not mean that the aerosol is free of potentially harmful substances.

Topics that may be discussed include:

• Potential airway irritation
• Nicotine addiction
• Exposure to chemicals and metals
• Risk of acute lung injury
• Effects on asthma and chronic lung disease
• Risks associated with THC-containing products
• Importance of seeking medical care for new respiratory symptoms

Note: Education should be factual and specific to the patient’s situation.

Vaping vs. Cigarette Smoking

Traditional cigarettes and vaping devices expose the respiratory system to different mixtures of chemicals. Combustible cigarette smoke contains thousands of chemicals and is strongly associated with COPD, lung cancer, cardiovascular disease, and numerous other conditions.

Vaping does not involve the same combustion process, but that does not make vaping harmless. Electronic cigarette aerosols can still contain nicotine, toxic chemicals, ultrafine particles, and metals.

Respiratory therapists should avoid presenting vaping as completely safe while also recognizing that the toxicology of vaping and cigarette smoke is not identical.

Dual Use

Some individuals both smoke cigarettes and use electronic cigarettes. This is known as dual use.

A patient may believe that reducing cigarette consumption while continuing to vape eliminates most smoking-related risk. However, continued exposure to cigarette smoke still carries substantial health consequences.

When obtaining a tobacco history, clinicians should ask about both conventional cigarette smoking and vaping rather than treating them as mutually exclusive behaviors.

Adolescents and Young Adults

Vaping is especially important in adolescent and young adult populations. Nicotine exposure during adolescence can contribute to dependence, and younger individuals may be attracted to flavored products or devices designed to be discreet.

Respiratory therapists working in emergency departments, pediatric settings, pulmonary clinics, or community health may encounter younger patients who use vaping products regularly. Education should be appropriate for the patient’s age and focused on respiratory health, addiction, and the potential consequences of repeated exposure.

Occupational and Clinical Considerations for Respiratory Therapists

Vaping history should become part of routine respiratory assessment when clinically relevant. Respiratory therapists may encounter vaping-related problems across multiple care settings, including:

• Emergency departments
• Intensive care units
• Pulmonary function laboratories
• Asthma clinics
• Sleep centers
• Pediatric units
• General hospital floors
• Outpatient pulmonary clinics

Note: Recognition of vaping exposure can help explain otherwise unclear respiratory symptoms. However, vaping should be treated as one component of the clinical history rather than assumed to be the diagnosis.

Important Assessment Questions for RT Students

Students should become comfortable asking patients about vaping in the same way they ask about cigarette smoking, occupational exposure, medications, and respiratory history.

A concise assessment might determine:

• Do you currently vape?
• What substances do you vape?
• How often do you vape?
• When did you last vape?
• Do you use nicotine, THC, or both?
• Where do you obtain the products?
• Have you recently changed products?
• Did your symptoms begin after increased use or a new product?

Note: These questions can provide valuable clues without significantly prolonging the assessment.

When to Suspect Significant Vaping-Related Lung Injury

Respiratory therapists should consider vaping-related lung injury when a patient with recent vaping exposure develops unexplained respiratory symptoms, especially when symptoms are accompanied by hypoxemia, bilateral pulmonary infiltrates, gastrointestinal complaints, or systemic symptoms.

The suspicion becomes stronger when common alternative diagnoses are not fully supported by the clinical findings. However, vaping history alone is not sufficient to diagnose EVALI. A thorough evaluation for infection and other cardiopulmonary conditions is still necessary.

Emergency Warning Signs

Patients who vape should seek urgent medical evaluation when they develop signs of significant respiratory compromise. Concerning findings include severe shortness of breath, persistent chest pain, cyanosis, confusion, rapidly worsening cough, marked tachypnea, or low oxygen saturation.

In the clinical setting, these findings should prompt rapid assessment and stabilization. Early recognition of deteriorating gas exchange is especially important because some patients with inflammatory lung injury can worsen rapidly.

Prevention

The most effective way to prevent vaping-related pulmonary injury is to avoid inhaling vaping aerosols. Patients who do not currently vape should generally be discouraged from starting, particularly adolescents, young adults, pregnant individuals, and people with chronic respiratory disease.

Patients who already vape may benefit from counseling regarding nicotine dependence and cessation strategies.

Respiratory therapists can support these efforts by providing clear information about respiratory effects and directing patients to appropriate cessation resources.

Role of the Respiratory Therapist

Respiratory therapists play several roles in the care of patients affected by vaping. These may include performing respiratory assessments, obtaining exposure histories, monitoring oxygen saturation, administering oxygen, providing aerosol therapy, collecting arterial blood gases, assisting with airway management, initiating and monitoring ventilatory support, and educating patients.

RTs may also help identify deterioration before severe respiratory failure develops.

In critically ill patients, respiratory therapists contribute to lung-protective ventilator management, oxygen titration, airway care, secretion management, and repeated evaluation of the patient’s response to treatment.

Understanding vaping-related disease allows the RT to connect exposure history with respiratory findings while still considering a broad differential diagnosis.

Key Clinical Considerations

Several principles are important when evaluating patients who vape.

• Vaping products vary widely in composition, so the exact exposure may be difficult to determine.
• Respiratory symptoms associated with vaping can resemble many other pulmonary conditions.
• Vaping-related lung injury can range from mild irritation to severe hypoxemic respiratory failure.
• Gastrointestinal and constitutional symptoms may accompany the respiratory presentation.
• Respiratory care is primarily supportive and should be guided by the patient’s physiologic needs rather than vaping history alone.

Vaping Practice Questions

1. What is vaping?
Vaping is the use of an electronic device to heat a liquid and create an aerosol that is inhaled into the lungs.

2. What are e-cigarettes?
E-cigarettes are electronic nicotine delivery devices that heat a liquid to produce an inhaled aerosol.

3. Why is vaping important in respiratory care?
Vaping is important because it exposes the lungs to inhaled chemicals, nicotine, flavoring agents, and other substances that may affect respiratory health.

4. Should respiratory therapists ask patients about vaping?
Yes. Vaping history should be included in the respiratory assessment along with smoking, occupational exposure, and environmental exposure.

5. Why should clinicians ask specifically about vaping instead of only asking about smoking?
Some patients who vape do not consider themselves smokers, so asking only about smoking may miss important exposure history.

6. What details should be included in a vaping history?
A vaping history may include the type of device, frequency of use, duration of use, nicotine concentration, substances vaped, and symptoms related to vaping.

7. How is vaping related to tobacco-use assessment?
Vaping is grouped with tobacco-related and nicotine-delivery products, so it should be assessed as part of the patient’s tobacco and inhaled exposure history.

8. Why should nicotine concentration be documented in patients who vape?
Nicotine concentration helps estimate addiction risk and the amount of nicotine exposure from the vaping product.

9. What respiratory symptoms may be associated with vaping?
Symptoms may include cough, shortness of breath, chest pain, wheezing, and worsening breathing difficulty.

10. What non-respiratory symptoms may occur with vaping-associated lung injury?
Non-respiratory symptoms may include fever, vomiting, diarrhea, headache, dizziness, nausea, and rapid heart rate.

11. What is EVALI?
EVALI stands for e-cigarette or vaping product use-associated lung injury.

12. When was EVALI first identified as a major clinical concern?
EVALI was first identified as a major clinical concern in 2019.

13. What are other names for EVALI?
EVALI may also be called vaping-associated pulmonary injury or vaping-associated lung injury.

14. Is EVALI always a mild condition?
No. EVALI can be severe, require ICU admission, lead to respiratory failure, and may be fatal.

15. What percentage of EVALI patients may require ICU admission?
More than 50% of patients with EVALI may require admission to an intensive care unit.

16. What imaging finding is commonly used in the diagnosis of EVALI?
Pulmonary infiltrates on chest x-ray or computed tomography are commonly used in the diagnostic evaluation.

17. Is there one single diagnostic test for EVALI?
No. EVALI is diagnosed through clinical evaluation, vaping history, imaging findings, and exclusion of other causes.

18. What conditions must be ruled out when evaluating possible EVALI?
Conditions such as pneumonia, influenza, COVID-19, and other causes of acute lung disease should be ruled out.

19. What time frame of vaping exposure is commonly used in EVALI case guidance?
Pulmonary infiltrates occurring within 90 days of e-cigarette or vaping product use are commonly used in case guidance.

20. What laboratory finding may be seen in patients with EVALI?
An elevated white blood cell count may be seen, although laboratory findings are nonspecific.

21. What treatment may be used for EVALI-related lung inflammation?
Corticosteroids may be used in some cases to help reduce lung inflammation.

22. Why might antibiotics or antivirals be used in suspected EVALI?
They may be used while clinicians evaluate and rule out infectious causes of the patient’s symptoms.

23. What supportive therapy may be needed for hypoxemic patients with EVALI?
Supportive oxygenation may be needed, including supplemental oxygen or ventilatory support in severe cases.

24. Why is follow-up important after hospitalization for EVALI?
Follow-up is important to monitor recovery, reassess lung function, evaluate persistent symptoms, and reinforce vaping cessation.

25. What should patients with EVALI be advised to do after discharge?
They should be advised to stop vaping and follow up with a pulmonologist or appropriate healthcare provider.

26. Why is nicotine addiction a major concern with vaping?
Nicotine addiction is a major concern because many vaping devices deliver high doses of nicotine that can lead to dependence.

27. How much nicotine may be found in a small e-cigarette liquid pod?
A small liquid pod may contain a nicotine dose equivalent to a pack of cigarettes.

28. Why are adolescents especially vulnerable to nicotine exposure?
Adolescents are especially vulnerable because nicotine can affect the developing brain and increase the risk of long-term addiction.

29. How can e-cigarette use affect future cigarette smoking risk?
E-cigarette use may increase the risk of progressing to daily cigarette smoking, especially among young users.

30. According to the information provided, how much more likely are e-cigarette users to progress to daily cigarette smoking?
E-cigarette users are three times more likely to progress to daily cigarette smoking compared with those who never use e-cigarettes.

31. Why is vaping considered a youth public health concern?
Vaping is a youth public health concern because it can introduce adolescents and young adults to nicotine addiction and other tobacco products.

32. What is the safest recommendation for patients after suspected vaping-related lung injury?
The safest recommendation is to stop vaping completely and avoid further exposure to e-cigarette or vaping products.

33. How can vaping contribute to airway irritation?
Vaping can expose the airways to heated chemicals, flavoring agents, and aerosols that may irritate lung tissue.

34. Why is trying tobacco before age 18 concerning?
Trying tobacco before age 18 is concerning because early nicotine exposure is associated with progression to cigarette smoking and long-term dependence.

35. What does dual use mean?
Dual use means a person uses more than one tobacco or nicotine product, such as cigarettes and e-cigarettes.

36. Why is dual use clinically important?
Dual use is important because the patient may continue cigarette smoke exposure while also maintaining nicotine addiction through vaping.

37. Why is it important to ask about vaping frequency?
Frequency helps estimate the amount of exposure and the possible relationship between vaping and respiratory symptoms.

38. Why should respiratory therapists ask about all nicotine products?
Respiratory therapists should ask about all nicotine products because patients may use cigarettes, e-cigarettes, smokeless tobacco, hookah, or other inhaled substances.

39. What is chemical pneumonitis?
Chemical pneumonitis is lung inflammation caused by inhaling irritating or toxic chemical substances.

40. Does uncertainty about long-term effects mean vaping should be considered safe?
No. Uncertainty does not mean vaping is safe, especially because known concerns include nicotine addiction, chemical exposure, and lung injury.

41. Why are flavored e-cigarettes concerning?
Flavored e-cigarettes are concerning because flavoring chemicals may be harmful when heated and inhaled into the lungs.

42. What is diacetyl associated with?
Diacetyl is associated with serious lung disease, including bronchiolitis obliterans.

43. What is bronchiolitis obliterans sometimes called?
Bronchiolitis obliterans is sometimes called popcorn lung.

44. Why does a pleasant flavor not make vaping safe?
A pleasant flavor does not make vaping safe because chemicals that are safe to taste or eat may not be safe to inhale after heating.

45. What harmful metals may be found in vaping aerosols?
Harmful metals may include nickel, tin, and lead.

46. What carrier substances are commonly found in e-cigarette liquids?
Vegetable glycerin and propylene glycol are common carrier substances found in e-cigarette liquids.

47. What other harmful substances may be present in e-cigarette aerosols?
E-cigarette aerosols may contain carcinogens, volatile organic compounds, heavy metals, flavoring chemicals, and nicotine.

48. Why can device design make youth vaping harder to detect?
Some vaping devices resemble pens, USB flash drives, or other everyday objects, making them easy to hide.

49. What does the AARC position statement say about e-cigarettes?
The AARC opposes the use of e-cigarettes, vapes, or devices used to aerosolize nontherapeutic liquids for inhalation.

50. Does the AARC recommend e-cigarettes as a smoking cessation method?
No. The AARC does not recommend e-cigarettes as a smoking cessation method.

51. What smoking cessation strategies are recommended instead of e-cigarettes?
Evidence-based smoking cessation strategies include FDA-approved medications, behavioral counseling, and follow-up support.

52. Why is counseling important for patients trying to quit nicotine?
Counseling helps patients understand triggers, build coping strategies, stay motivated, and reduce the chance of relapse.

53. What combination works best for smoking cessation?
A combination of medication and behavioral counseling works best for smoking cessation.

54. What role can respiratory therapists play in smoking cessation?
Respiratory therapists can assess tobacco use, educate patients, provide cessation counseling, and connect patients with treatment resources.

55. Why may hospitalization be a good time to discuss nicotine cessation?
Hospitalized patients may be more motivated to quit because their illness may be related to tobacco use and hospitals are smoke-free environments.

56. What should respiratory therapists avoid telling patients about vaping?
They should avoid telling patients that vaping is harmless or a proven safe replacement for smoking.

57. Why should respiratory therapists use a nonjudgmental approach when asking about vaping?
A nonjudgmental approach helps patients feel comfortable giving honest information about nicotine, THC, or other vaping product use.

58. What substances may patients vape besides nicotine?
Patients may vape THC, CBD, flavoring chemicals, homemade liquids, or other inhaled substances.

59. What is THC?
THC is tetrahydrocannabinol, the psychoactive compound found in marijuana.

60. What is CBD?
CBD is cannabidiol, a compound found in cannabis products that may be included in some vaping liquids.

61. Why are THC-containing vaping products clinically important?
THC-containing vaping products have been associated with many cases of EVALI and should be specifically assessed.

62. What does “dabbing” refer to in vaping history?
Dabbing refers to inhaling concentrated drugs or substances that are heated before vaping.

63. Why should clinicians ask whether cartridges or pods were shared?
Shared cartridges or pods may increase exposure risk and help clinicians understand the patient’s vaping behavior.

64. Why should clinicians ask whether old cartridges were reused?
Reused cartridges may have been refilled with homemade or commercial products, which can increase exposure to unknown substances.

65. What device details should be reported in suspected EVALI?
Clinicians should document the type of device used, such as bottles, cartridges, pods, or refillable systems.

66. What liquid details should be reported in suspected EVALI?
Clinicians should document whether the liquid contained nicotine, THC, CBD, flavorings, or other substances.

67. What vaping behavior details may be clinically useful?
Useful details include frequency of puffs, cloud volume, stealth vaping, zero vaping, and use of a Valsalva maneuver after inhalation.

68. Why is cloud volume relevant in vaping history?
Cloud volume may help estimate the amount of aerosol exposure and intensity of vaping behavior.

69. What is stealth vaping?
Stealth vaping refers to vaping in a way that minimizes visible aerosol so the behavior is harder to detect.

70. Why might patients with EVALI require mechanical ventilation?
They may develop severe respiratory failure that prevents adequate oxygenation or ventilation without support.

71. What does CT imaging often show in EVALI?
CT imaging may show infiltrates in both lungs.

72. What bronchoscopy finding may be seen in some EVALI cases?
Bronchoscopy with bronchoalveolar lavage may show neutrophilia and lipid-laden macrophages.

73. Are lipid-laden macrophages specific for EVALI?
No. Lipid-laden macrophages may be present but are not specific enough to diagnose EVALI alone.

74. What staining methods may be used to identify lipid-laden macrophages?
Oil Red O staining or Sudan staining may be used.

75. Why should suspected EVALI cases be reported?
Reporting helps public health agencies track cases, investigate causes, and identify harmful products or exposure patterns.

76. What is the main respiratory care takeaway about vaping?
The main takeaway is that vaping should be assessed, documented, and addressed as a clinically important inhaled exposure.

77. Why should vaping be included in bedside assessment?
Vaping should be included because it may affect pulmonary health and contribute to respiratory symptoms or disease risk.

78. Why should respiratory therapists ask about recent changes in vaping products?
Recent changes in devices, liquids, cartridges, or substances may help identify a possible trigger for new respiratory symptoms.

79. Why can EVALI be difficult to recognize at first?
EVALI can be difficult to recognize because its symptoms can resemble pneumonia, influenza, COVID-19, or other acute respiratory illnesses.

80. Why is vaping especially important to assess in young patients with unexplained dyspnea?
Young patients may vape even if they do not smoke cigarettes, and recent vaping can be linked to acute lung injury.

81. Why is vaping included with other inhaled exposures?
Vaping is included because it introduces substances directly into the respiratory tract, similar to other inhaled risks.

82. What patient statement may require clarification during assessment?
A patient who says they do not smoke may still vape, so the clinician should ask directly about e-cigarette use.

83. What is one reason vaping may be mistakenly viewed as safe?
Vaping may be viewed as safe because it does not produce traditional cigarette smoke.

84. Why is the term “vapor” potentially misleading?
The term “vapor” may be misleading because e-cigarettes create an aerosol that can contain nicotine, metals, chemicals, and other harmful substances.

85. What does the AARC tobacco-use-control statement support?
It supports eliminating tobacco use and exposure to inhaled toxic substances, including electronic cigarettes and vaping devices.

86. What types of inhaled substances are included in the AARC tobacco-use-control concern?
The concern includes tobacco, marijuana, electronic cigarettes, water-pipe smoking, vaping devices, and other inhaled toxic substances.

87. What should medical facilities do for patients who use tobacco or inhaled substances?
Medical facilities should identify these patients and provide interventions, pharmacotherapy, counseling, and follow-up when appropriate.

88. What type of respiratory therapist is strongly encouraged for tobacco-use treatment?
Respiratory therapists trained as tobacco treatment specialists are strongly encouraged.

89. Why is vaping relevant to community health promotion?
Vaping is relevant because it affects youth prevention, nicotine addiction, respiratory health education, and public awareness.

90. What educational materials may include e-cigarette information?
Educational kits for tobacco use, asthma, COPD, and e-cigarette use may include information about vaping risks.

91. Why should respiratory therapists educate families about vaping devices?
Families may not recognize vaping devices because some look like pens, USB drives, or everyday electronic items.

92. What is one danger of liquid nicotine solutions in children?
Liquid nicotine solutions can cause toxic exposure, and poison control centers have reported increasing calls related to these exposures.

93. Why is nicotine delivery to the brain concerning in newer devices?
Newer devices can deliver large amounts of nicotine to the brain, increasing addiction risk and potential harm to developing brains.

94. Why should vaping history include the duration of use?
Duration helps clinicians estimate the length of exposure and determine whether vaping may be related to current respiratory symptoms.

95. What should respiratory therapists recommend instead of vaping for quitting smoking?
RTs should support FDA-approved medications, behavioral counseling, and evidence-based cessation programs.

96. Why is follow-up important in tobacco cessation?
Follow-up helps monitor progress, reinforce quitting, manage relapse risk, and connect patients with continued support.

97. What is one major concern about marketing e-cigarettes to young people?
Marketing may encourage nicotine addiction in children, adolescents, and young adults.

98. Why are developing countries mentioned in relation to tobacco marketing?
They are mentioned because the tobacco industry has targeted developing countries as part of expanding tobacco and nicotine product use.

99. What is the relationship between vaping and patient education?
Vaping should be addressed during patient education because patients may misunderstand its risks and addiction potential.

100. What is the overall message about vaping in respiratory care?
The overall message is that vaping is not harmless and should be included in respiratory assessment, education, prevention, and cessation support.

Final Thoughts

Vaping is an important consideration in respiratory care because inhaled aerosols can affect the airways, lung tissue, pulmonary defenses, and gas exchange. Respiratory therapists should obtain a clear vaping history when evaluating unexplained cough, dyspnea, hypoxemia, chest discomfort, or abnormal pulmonary imaging.

Patients with severe vaping-related lung injury may require oxygen therapy, high-flow nasal cannula, mechanical ventilation, or other forms of respiratory support.

At the same time, clinicians should maintain a broad differential diagnosis and avoid attributing every respiratory problem to vaping. Careful assessment, supportive treatment, patient education, and recognition of respiratory deterioration remain central to effective management.